Anavex Life Sciences Corp. (NASDAQ:AVXL) saw an upside of 14.76% to $9.22 after adding $1.19 on Wednesday. The 5-day average trading volume is 948,965 shares of the company’s common stock. It has gained $9.29 in the past week and touched a new high 3 times within the past 5 days. An average of 716,856 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 896,122.
AVXL’s 1-month performance is 7.03% or $1.00 on its low of $7.58 reached on 08/08/23. The company’s shares have touched a 52-week low of $7.44 and high of $15.24, with the stock’s rally to the 52-week high happening on 02/07/23. YTD, AVXL has lost -0.49% or -$0.10 and has reached a new high 9 times. However, the current price is down -39.53% from the 52-week high price.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
AVXL stock investors last saw insider trading activity on Jun 28.MISSLING CHRISTOPHER U (President and CEO) most recently sold 268,000 shares at $7.98 per share on Jun 28. This transaction cost the insider $2,139,310.
Valuation Metrics
AVXL stock has a beta of 0.68. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 4.98.
Anavex Life Sciences Corp.’s quick ratio for the recent period was 11.40, with the current ratio over the same period at 11.40. The firm’s gross profit as reported stood at $3.37 million against revenue of $50.99 million.
Earnings Surprise
Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 100.0% to -$13.11 million, while revenue of -$12.97 million was 1.07% off the previous quarter. EBITDA for the quarter stood at more than -$14.19 million. Shareholders hold equity totaling $80.84 million.
Let’s look briefly at Anavex Life Sciences Corp. (AVXL) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 69.08% to suggest the stock is trending Neutral, with historical volatility in this time period at 79.58%.
The stock’s 5-day moving average is $8.28, reflecting a +11.44% or $0.94 change from its current price. AVXL is currently trading +7.13% above its 20-day SMA, -3.98% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -1.72% and SMA200 by-17.85%.
Stochastic %K and %D was 49.36% and 45.38% and the average true range (ATR) pointed at 0.45. The RSI (14) points at 63.86%, while the 14-day stochastic is at 92.39% with the period’s ATR at 0.40. The stock’s 9-day MACD Oscillator is pointing at 0.07 and 0.15 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for Anavex Life Sciences Corp. (NASDAQ: AVXL), Cantor Fitzgerald downgraded it to a Neutral rating. They previously had an Overweight rating on the stock.
